Compositions and methods for treating and preventing proteinuria and endothelial erosion

Abstract

In some embodiments, a system and/or method may inhibit and/or ameliorate proteinuria and related comorbidities in a subject. In some embodiments, proteinuria and/or Endothelial Erosion (EE)™ and related comorbidities may be inhibited and/or ameliorated by adjusting a subject's zeta potential to at least within acceptable levels associated with a healthy subject. A subject's zeta potential may be adjusted by administering pharmaceutical compositions which: increases a negative electrostatic potential of various tissues in a subject; increases the negative electrical surface charges of a subject's blood cells, plasma proteins and/or glycocalyx; and/or adjusts various properties of a subject's bloodstream (e.g., the blood serum pH). In some embodiments, Proteinuria and/or Endothelial Erosion (EE)™ and related comorbidities may be inhibited and/or ameliorated by: adjusting a subject's blood serum pH; repairing damage to the glycocalyx in a subject; and/or increasing blood flow, supply essential elements and/or replenish essential elements lost through proteinuria.

What is claimed: 
     
         1 . A therapeutic composition to alleviate proteinuria in a human patient by reducing permeability of the vascular endothelial surface layer comprising:
 1) an oral dose of a component of vascular endothelial glycocalyx comprising hyaluronic acid;   2) an oral dose of lactoferrin in a therapeutically effective amount to increase serum levels of transferrin;   3) an oral dose of a pharmaceutically effective amount of chondroitin and glucosamine, wherein the effective amount increases the serum zeta potential by reducing hypercoagulation of erythrocytes; and   4) a sulfur compound selected from the group consisting of methylsulfonylmethane (MSM), heparan sulfate, magnesium sulfate, N-acetyl glucosamine, a sulfur derivative of the chondroitin, a sulfur derivative of the glucosamine, and combinations thereof.   
     
     
         2 . The composition of  claim 1 , wherein the sulfur compound is methylsulfonylmethane to ameliorate damage to the endothelial surface layer. 
     
     
         3 . The composition of  claim 1  further tocotrienols. 
     
     
         4 . The composition of  claim 3 , wherein the tocotrienols are comprised of delta and gamma tocotrienols in a 90:10 ratio respectively. 
     
     
         5 . The composition of  claim 1 , further comprising a compound selected form the group consisting of nattokinase, potassium citrate, and olive leaf extract and combinations thereof. 
     
     
         6 . The composition of  claim 1  further comprising N-acetyl cysteine. 
     
     
         7 . The composition of  claim 1  further comprising magnesium. 
     
     
         8 . The composition of  claim 1 , wherein the hyaluronic acid, glucosamine, chondroitin and lactoferrin are combined in an oral form having a predetermined unit dose effective to decrease excess urinary protein excretion. 
     
     
         9 . The composition of  claim 1 , further comprising an intravenous dose of albumin.